Dapzole

Therapeutic Segment:
Anti-ulcerant

Generic Name:
Pantoprazole Sodium

Description:
Dapzole (Pantoprazole Sodium) Delayed-Release Tablets, a PPI, is a substituted benzimidazole, sodium 5-(difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridinyl) methyl] sulfinyl]-1H-benzimidazole sesquihydrate, a compound that inhibits gastric acid secretion. Its empirical formula is C16H14F2N3NaO4S . 1.5 H2O, with a molecular weight of 432.4g/mol.

Indication:

Pantoprazole is indicated for use in adults and adolescents 12 years of age and above for:

  • Symptomatic gastrooesophageal reflux disease.
  • long-term management and prevention of relapse in reflux oesophagitis. For long-term management and prevention of relapse in reflux oesophagitis.
  • Pantoprazole is indicated for use in adults for: Prevention of gastroduodenal ulcers induced by non-selective non-steroidal anti-inflammatory drugs (NSAIDs) in patients at risk with a need for continuous NSAID treatment.

Formulation:

  • Tablets

Strength:

  • 40MG

Pack Size:

  • 1 x 14s
Dapzole-packshot-Mirror